免疫检查点抑制剂在淋巴瘤中的研究进展

肿瘤细胞利用免疫检查点通路来逃避宿主免疫系统并抑制免疫细胞功能.癌细胞表达程序性细胞死亡蛋白配体1/2(programmed death-ligand 1/2,PD-L1/PD-L2)与细胞毒性 T 细胞上存在的程序性细胞死亡蛋白 1(programmed cell death protein-1,PD-1)结合,触发...

Research progress of immune checkpoint blockade in lymphoma

Tumor cells exploit immune checkpoint pathways to evade the host immune system and suppress immune cell function.Cancer cells express programmed death-ligand 1/2(PD-L1/PD-L2)and bind to programmed cell death protein-1(PD-1)present on cytotoxic T cells,triggering inhibitory signal transduction and reducing cellular toxicity and T cell exhaustion.Targeting the PD-1 pathway significantly enhances the cytotoxic activity of T cells,thereby inducing tumor cell lysis.Immune checkpoint blockade can suppress this signal,rendering it an effective treatment strategy for cancer patients.In recent years,we have witnessed unprecedented clinical efficacy of immunotherapies involving PD-1 or PD-L1 blockade in treating advanced cancers,including hematologic malignancies,supporting the essential roles of PD-1 and PD-L1 in immune suppression.This article reviews clinical research into PD-1/PD-L1–related pathway drugs in lymphoma.